Polaris Group (TPE:6550) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6550 Polaris Group TPE:6550
57 GF Score
Price NT$12.20
GF Value NT$55.63
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Polaris Group FFO per Share?

FFO per Share only applies to REITs.

TPE:6550
57GF Score
Polaris Group TPE:6550
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Polaris Group (TPE:6550) Overvalued in 2026?

Based on GuruFocus' analysis, Polaris Group stock appears to be undervalued. The current stock price of NT$12.20 is trading 78.1% below its estimated GF Value™ of NT$55.63. GuruFocus considers Polaris Group to be Possible Value Trap.

Key valuation signals for TPE:6550:

  • FFO per Share:
  • GF Value™: NT$55.63 vs. price of NT$12.20 (78.1% below fair value)
  • GF Score™: 57/100 with 6 warning signs

No single metric tells the full story. See the TPE:6550 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Polaris Group Business Description

Address Ugland House, PO Box 309, Grand Cayman, CYM, KY1-1104
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. The company's lead therapeutic Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is also involved in every stage of the drug development process.
57GF Score

Get the complete analysis for TPE:6550

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$12.20
Price
NT$55.63
GF Value